Amorphous Tetracyclic Compound Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The tetracyclic compound represented by formula (I) has poor water solubility and bioavailability when administered orally, limiting its effectiveness as a therapeutic agent for diseases associated with ALK abnormalities.
Innovation Solution
The development of amorphous forms of the tetracyclic compound, particularly its hydrochloride, and solid dispersions containing these forms, which exhibit improved physical and chemical stability and solubility, achieved through spray drying and incorporation with inert carriers like cellulose derivatives and water-soluble synthetic polymers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the tetracyclic compound is administered in crystalline form, then manufacturing and storage stability are maintained, but water solubility and bioavailability are poor
Solution Approach 1:
The patent applies parameter changes by transforming the compound from crystalline to amorphous form, fundamentally altering its physical state parameters. This phase transition enables the compound to achieve both high solubility and stability, as the amorphous form provides enhanced molecular mobility and interaction with water while maintaining structural integrity through controlled preparation methods
Solution Approach 2:
The patent employs composite materials by creating solid dispersions that combine the amorphous tetracyclic compound with carrier substances. This composite approach allows the compound to benefit from both the high solubility of the amorphous form and the stability provided by the carrier matrix, achieving synergistic effects that resolve the solubility-stability contradiction
2Quantity of substance
If the tetracyclic compound is administered in amorphous form, then water solubility and bioavailability are improved, but physical stability may be compromised
Solution Approach 1:
The patent uses intermediary substances as carriers in solid dispersion formulations to mediate between the amorphous compound and the environment. These carriers act as protective matrices that maintain the amorphous state of the compound while providing structural support and stability, preventing unwanted crystallization or degradation
Solution Approach 2:
The patent applies preliminary action through controlled preparation methods that create the amorphous form under specific conditions before formulation. By controlling the preparation process parameters and using stabilizing agents during manufacturing, the amorphous form is created with inherent stability properties that prevent subsequent crystallization or degradation
3Reliability
If higher doses of the tetracyclic compound are used to improve efficacy, then therapeutic effect increases, but side effects and toxicity may increase
Solution Approach 1:
The patent applies parameter changes by altering the physical form of the compound from crystalline to amorphous, which changes the dose-response relationship. The amorphous form provides enhanced bioavailability and cellular uptake efficiency, allowing therapeutic effects to be achieved at lower doses, thereby reducing side effects and toxicity while maintaining efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous forms and solid dispersions enhance solubility and bioavailability, allowing for reduced daily doses and improved stability, making them suitable for oral and parenteral drug formulations.
Implementation Method 1
amorphous forms of hydrochlorides of the tetracyclic compound represented by the formula (I) below have a very high physical stability and an excellent solubility
Implementation Method 2
spraying the feed solution obtained in the step (i); and drying the sprayed feed solution to provide the amorphous form
Data Source
AI summary
An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.